博济医药(300404) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥103,299,782.23, representing a 39.25% increase compared to ¥74,184,304.67 in the same period last year[5] - The net profit attributable to shareholders decreased by 6.03% to ¥11,738,526.83 from ¥12,461,872.32 year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 97.55% to ¥7,129,018.83 from ¥3,579,114.49 in the previous year[5] - The company's basic and diluted earnings per share decreased by 15.16% to ¥0.0319 from ¥0.0376 year-on-year[5] - The weighted average return on equity was 1.36%, down from 1.52% in the previous year[5] - The total operating revenue for the first quarter of 2023 was approximately ¥103.30 million, representing a year-over-year increase of 39.25%[17] - The net profit attributable to the parent company was approximately ¥11.74 million, a decrease of 6.03% compared to the previous year[17] - The net profit for Q1 2023 was CNY 12,344,811.55, a slight decrease of 5.0% from CNY 12,988,676.50 in Q1 2022[28] - The company reported a decrease in comprehensive income attributable to the parent company, totaling approximately 11.23 million yuan, down from 12.36 million yuan[29] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥28,686.02, a decline of 100.22% compared to ¥13,226,796.84 in the same period last year[12] - The net cash flow from financing activities increased by 296.28% to ¥24,654,969.45, compared to -¥12,561,361.04 in the same period last year, mainly due to increased borrowings[12] - The company experienced a 90.98% improvement in net cash flow from investing activities, which was -¥19,483,138.77, compared to -¥215,913,864.22 in the previous year[12] - The company’s cash and cash equivalents at the end of Q1 2023 were CNY 311,609,538.92, compared to CNY 306,925,967.42 at the beginning of the year[23] - The total assets at the end of the reporting period were ¥1,298,935,407.70, an increase of 2.65% from ¥1,264,455,710.99 at the end of the previous year[5] - The total assets as of March 31, 2023, amounted to CNY 1,298,935,407.70, an increase from CNY 1,265,433,029.25 at the beginning of the year[25] - The company’s inventory increased to CNY 188,327,503.34 from CNY 168,362,996.60 at the beginning of the year, reflecting a growth of 11.9%[23] - The company’s short-term borrowings rose to CNY 32,555,686.29 from CNY 20,230,248.24, indicating a significant increase of 60.0%[24] Operating Costs and Revenue - The company reported a significant increase in operating costs, which rose by 49.95% to ¥62,805,195.55, primarily due to increased revenue[11] - The total operating costs for Q1 2023 were CNY 95,145,102.03, up 37.9% from CNY 69,042,568.57 in Q1 2022[28] - The cash received from sales of goods and services was approximately 105.62 million yuan, an increase from 83.94 million yuan in the previous year[31] - The company received high-tech enterprise certification for its wholly-owned subsidiary, Shenzhen Borui Pharmaceutical Technology Co., Ltd., valid for three years[19] Future Plans and Developments - The company plans to raise up to ¥84 million through a private placement of shares at a price of ¥7.04 per share, with the funds intended to supplement working capital[18] - The company is actively pursuing the development of traditional Chinese medicine, supported by recent government initiatives to enhance the sector[17] - The company secured new contract amounts of approximately ¥169 million, which is a decrease compared to the same period last year due to delays in some ongoing projects[17] - The company reported a nearly 86% year-over-year increase in new orders for traditional Chinese medicine projects, totaling approximately ¥60 million[17] - The company plans to grant 3.5 million restricted stock options under the 2023 incentive plan, with an initial grant price of CNY 5.47 and CNY 8.75 per share for different categories[20] Shareholder Information - The company has a total of 15,939 common stock shareholders at the end of the reporting period[14] - The largest shareholder, Wang Tingchun, holds 29.00% of the shares, amounting to approximately 106.91 million shares, with 80.19 million shares pledged[14]